WO1998030221A1 - Composition de type emulsion huile/eau a usage ophtalmique et contenant du difluprednate - Google Patents
Composition de type emulsion huile/eau a usage ophtalmique et contenant du difluprednate Download PDFInfo
- Publication number
- WO1998030221A1 WO1998030221A1 PCT/JP1998/000048 JP9800048W WO9830221A1 WO 1998030221 A1 WO1998030221 A1 WO 1998030221A1 JP 9800048 W JP9800048 W JP 9800048W WO 9830221 A1 WO9830221 A1 WO 9830221A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- difluprednate
- emulsion
- oil
- weight
- present
- Prior art date
Links
- WYQPLTPSGFELIB-JTQPXKBDSA-N Difluprednate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2CC[C@@](C(=O)COC(C)=O)(OC(=O)CCC)[C@@]2(C)C[C@@H]1O WYQPLTPSGFELIB-JTQPXKBDSA-N 0.000 title claims abstract description 104
- 229960004875 difluprednate Drugs 0.000 title claims abstract description 102
- 239000000203 mixture Substances 0.000 title claims abstract description 66
- 239000007764 o/w emulsion Substances 0.000 title 1
- 239000000839 emulsion Substances 0.000 claims abstract description 83
- 150000003904 phospholipids Chemical class 0.000 claims abstract description 47
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 28
- 239000003921 oil Substances 0.000 claims description 38
- 229940057995 liquid paraffin Drugs 0.000 claims description 27
- 150000003839 salts Chemical class 0.000 claims description 15
- 239000002253 acid Substances 0.000 claims description 12
- 239000002738 chelating agent Substances 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 6
- 239000002997 ophthalmic solution Substances 0.000 claims description 4
- 229940054534 ophthalmic solution Drugs 0.000 claims description 4
- 150000001413 amino acids Chemical class 0.000 claims description 3
- 239000003755 preservative agent Substances 0.000 claims description 3
- 239000003381 stabilizer Substances 0.000 claims description 3
- 239000003963 antioxidant agent Substances 0.000 claims description 2
- 239000000872 buffer Substances 0.000 claims description 2
- 230000002335 preservative effect Effects 0.000 claims description 2
- 239000002562 thickening agent Substances 0.000 claims description 2
- 230000003078 antioxidant effect Effects 0.000 claims 1
- 239000003002 pH adjusting agent Substances 0.000 claims 1
- 239000012929 tonicity agent Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 4
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 3
- 239000012530 fluid Substances 0.000 abstract description 2
- 230000009885 systemic effect Effects 0.000 abstract description 2
- 230000002411 adverse Effects 0.000 abstract 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 53
- 229940067631 phospholipid Drugs 0.000 description 43
- 235000019198 oils Nutrition 0.000 description 34
- 238000009472 formulation Methods 0.000 description 29
- 235000011187 glycerol Nutrition 0.000 description 25
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
- 239000003889 eye drop Substances 0.000 description 19
- 238000004090 dissolution Methods 0.000 description 17
- 238000002360 preparation method Methods 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- 238000004945 emulsification Methods 0.000 description 13
- 229920000609 methyl cellulose Polymers 0.000 description 13
- 239000001923 methylcellulose Substances 0.000 description 13
- 235000010981 methylcellulose Nutrition 0.000 description 13
- 239000000725 suspension Substances 0.000 description 13
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 12
- 239000012153 distilled water Substances 0.000 description 11
- LXAHHHIGZXPRKQ-UHFFFAOYSA-N 5-fluoro-2-methylpyridine Chemical compound CC1=CC=C(F)C=N1 LXAHHHIGZXPRKQ-UHFFFAOYSA-N 0.000 description 10
- -1 aliphatic amines Chemical class 0.000 description 10
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 10
- JQWAHKMIYCERGA-UHFFFAOYSA-N (2-nonanoyloxy-3-octadeca-9,12-dienoyloxypropoxy)-[2-(trimethylazaniumyl)ethyl]phosphinate Chemical compound CCCCCCCCC(=O)OC(COP([O-])(=O)CC[N+](C)(C)C)COC(=O)CCCCCCCC=CCC=CCCCCC JQWAHKMIYCERGA-UHFFFAOYSA-N 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 8
- 229920002678 cellulose Polymers 0.000 description 8
- 239000001913 cellulose Substances 0.000 description 8
- 238000004806 packaging method and process Methods 0.000 description 8
- 239000004302 potassium sorbate Substances 0.000 description 8
- 235000010241 potassium sorbate Nutrition 0.000 description 8
- 229940069338 potassium sorbate Drugs 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- 239000000126 substance Substances 0.000 description 7
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 6
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 239000001509 sodium citrate Substances 0.000 description 6
- 229960004926 chlorobutanol Drugs 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 5
- 235000011083 sodium citrates Nutrition 0.000 description 5
- 239000010409 thin film Substances 0.000 description 5
- 239000004698 Polyethylene Substances 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 235000019445 benzyl alcohol Nutrition 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 4
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 4
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 4
- 229960002216 methylparaben Drugs 0.000 description 4
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 4
- 229920000573 polyethylene Polymers 0.000 description 4
- 239000003549 soybean oil Substances 0.000 description 4
- 235000012424 soybean oil Nutrition 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 238000004659 sterilization and disinfection Methods 0.000 description 4
- FJKROLUGYXJWQN-UHFFFAOYSA-M 4-hydroxybenzoate Chemical compound OC1=CC=C(C([O-])=O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-M 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 239000004372 Polyvinyl alcohol Substances 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 3
- 229910052782 aluminium Inorganic materials 0.000 description 3
- 239000000607 artificial tear Substances 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 3
- 238000007922 dissolution test Methods 0.000 description 3
- 230000001804 emulsifying effect Effects 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000011888 foil Substances 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 3
- 150000004667 medium chain fatty acids Chemical class 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 3
- 229920002451 polyvinyl alcohol Polymers 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 3
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 2
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 206010010741 Conjunctivitis Diseases 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 235000019485 Safflower oil Nutrition 0.000 description 2
- 206010039705 Scleritis Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 235000010724 Wisteria floribunda Nutrition 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 208000010217 blepharitis Diseases 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 229940012356 eye drops Drugs 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000010408 film Substances 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- 229940119170 jojoba wax Drugs 0.000 description 2
- YLGXILFCIXHCMC-JHGZEJCSSA-N methyl cellulose Chemical compound COC1C(OC)C(OC)C(COC)O[C@H]1O[C@H]1C(OC)C(OC)C(OC)OC1COC YLGXILFCIXHCMC-JHGZEJCSSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 235000005713 safflower oil Nutrition 0.000 description 2
- 239000003813 safflower oil Substances 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 150000003408 sphingolipids Chemical class 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- CITHEXJVPOWHKC-UUWRZZSWSA-N 1,2-di-O-myristoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC CITHEXJVPOWHKC-UUWRZZSWSA-N 0.000 description 1
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical group CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 1
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 description 1
- RQALKBLYTUKBFV-UHFFFAOYSA-N 1,4-dioxa-7-thiaspiro[4.4]nonane Chemical compound O1CCOC11CSCC1 RQALKBLYTUKBFV-UHFFFAOYSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical class CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- URDCARMUOSMFFI-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]ethyl-(2-hydroxyethyl)amino]acetic acid Chemical compound OCCN(CC(O)=O)CCN(CC(O)=O)CC(O)=O URDCARMUOSMFFI-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-M 3-carboxy-2-(carboxymethyl)-2-hydroxypropanoate Chemical compound OC(=O)CC(O)(C(O)=O)CC([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-M 0.000 description 1
- BZISNWGGPWSXTK-UHFFFAOYSA-N 3-hydroxypropyl benzoate Chemical compound OCCCOC(=O)C1=CC=CC=C1 BZISNWGGPWSXTK-UHFFFAOYSA-N 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- 229920002567 Chondroitin Polymers 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical class [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 206010015084 Episcleritis Diseases 0.000 description 1
- 206010015946 Eye irritation Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010022941 Iridocyclitis Diseases 0.000 description 1
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- 239000004158 L-cystine Substances 0.000 description 1
- 235000019393 L-cystine Nutrition 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229940123973 Oxygen scavenger Drugs 0.000 description 1
- YYVFXSYQSOZCOQ-UHFFFAOYSA-N Oxyquinoline sulfate Chemical compound [O-]S([O-])(=O)=O.C1=C[NH+]=C2C(O)=CC=CC2=C1.C1=C[NH+]=C2C(O)=CC=CC2=C1 YYVFXSYQSOZCOQ-UHFFFAOYSA-N 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 235000019484 Rapeseed oil Nutrition 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- FBRAWBYQGRLCEK-UHFFFAOYSA-N [17-(2-chloroacetyl)-9-fluoro-10,13,16-trimethyl-3,11-dioxo-7,8,12,14,15,16-hexahydro-6h-cyclopenta[a]phenanthren-17-yl] butanoate Chemical compound C1CC2=CC(=O)C=CC2(C)C2(F)C1C1CC(C)C(C(=O)CCl)(OC(=O)CCC)C1(C)CC2=O FBRAWBYQGRLCEK-UHFFFAOYSA-N 0.000 description 1
- YEDTWOLJNQYBPU-UHFFFAOYSA-N [Na].[Na].[Na] Chemical compound [Na].[Na].[Na] YEDTWOLJNQYBPU-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 229960000250 adipic acid Drugs 0.000 description 1
- 239000003732 agents acting on the eye Substances 0.000 description 1
- 208000002205 allergic conjunctivitis Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 201000004612 anterior uveitis Diseases 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005261 aspartic acid Drugs 0.000 description 1
- 208000024998 atopic conjunctivitis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 238000010876 biochemical test Methods 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 235000010338 boric acid Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
- 239000001354 calcium citrate Substances 0.000 description 1
- UEAVLBXLOZNDHT-UHFFFAOYSA-K calcium;sodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxymethyl)amino]acetate Chemical compound [Na+].[Ca+2].OC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEAVLBXLOZNDHT-UHFFFAOYSA-K 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 1
- 229960005465 clobetasone butyrate Drugs 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 229960001270 d- tartaric acid Drugs 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- RNPXCFINMKSQPQ-UHFFFAOYSA-N dicetyl hydrogen phosphate Chemical compound CCCCCCCCCCCCCCCCOP(O)(=O)OCCCCCCCCCCCCCCCC RNPXCFINMKSQPQ-UHFFFAOYSA-N 0.000 description 1
- 229940093541 dicetylphosphate Drugs 0.000 description 1
- 229960003724 dimyristoylphosphatidylcholine Drugs 0.000 description 1
- 239000002526 disodium citrate Substances 0.000 description 1
- 235000019262 disodium citrate Nutrition 0.000 description 1
- CEYULKASIQJZGP-UHFFFAOYSA-L disodium;2-(carboxymethyl)-2-hydroxybutanedioate Chemical compound [Na+].[Na+].[O-]C(=O)CC(O)(C(=O)O)CC([O-])=O CEYULKASIQJZGP-UHFFFAOYSA-L 0.000 description 1
- 229960001484 edetic acid Drugs 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 231100000013 eye irritation Toxicity 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 229960002598 fumaric acid Drugs 0.000 description 1
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 229940031702 hydroxypropyl methylcellulose 2208 Drugs 0.000 description 1
- 229940031705 hydroxypropyl methylcellulose 2910 Drugs 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 201000004614 iritis Diseases 0.000 description 1
- 206010023332 keratitis Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- HWPKGOGLCKPRLZ-UHFFFAOYSA-M monosodium citrate Chemical compound [Na+].OC(=O)CC(O)(C([O-])=O)CC(O)=O HWPKGOGLCKPRLZ-UHFFFAOYSA-M 0.000 description 1
- 239000002524 monosodium citrate Substances 0.000 description 1
- 235000018342 monosodium citrate Nutrition 0.000 description 1
- 229940105132 myristate Drugs 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 229940125702 ophthalmic agent Drugs 0.000 description 1
- 239000008217 ophthalmic excipient Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229960001257 oxyquinoline sulfate Drugs 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N p-menthan-3-ol Chemical compound CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 229960003330 pentetic acid Drugs 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- PJAHUDTUZRZBKM-UHFFFAOYSA-K potassium citrate monohydrate Chemical compound O.[K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O PJAHUDTUZRZBKM-UHFFFAOYSA-K 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 239000010464 refined olive oil Substances 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229940001607 sodium bisulfite Drugs 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 229940037001 sodium edetate Drugs 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000004328 sodium tetraborate Substances 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- GNBVPFITFYNRCN-UHFFFAOYSA-M sodium thioglycolate Chemical compound [Na+].[O-]C(=O)CS GNBVPFITFYNRCN-UHFFFAOYSA-M 0.000 description 1
- 229940046307 sodium thioglycolate Drugs 0.000 description 1
- RPACBEVZENYWOL-XFULWGLBSA-M sodium;(2r)-2-[6-(4-chlorophenoxy)hexyl]oxirane-2-carboxylate Chemical compound [Na+].C=1C=C(Cl)C=CC=1OCCCCCC[C@]1(C(=O)[O-])CO1 RPACBEVZENYWOL-XFULWGLBSA-M 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- NJRXVEJTAYWCQJ-UHFFFAOYSA-N thiomalic acid Chemical compound OC(=O)CC(S)C(O)=O NJRXVEJTAYWCQJ-UHFFFAOYSA-N 0.000 description 1
- 150000003611 tocopherol derivatives Chemical class 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- JREYOWJEWZVAOR-UHFFFAOYSA-N triazanium;[3-methylbut-3-enoxy(oxido)phosphoryl] phosphate Chemical compound [NH4+].[NH4+].[NH4+].CC(=C)CCOP([O-])(=O)OP([O-])([O-])=O JREYOWJEWZVAOR-UHFFFAOYSA-N 0.000 description 1
- 235000013337 tricalcium citrate Nutrition 0.000 description 1
- VLPFTAMPNXLGLX-UHFFFAOYSA-N trioctanoin Chemical compound CCCCCCCC(=O)OCC(OC(=O)CCCCCCC)COC(=O)CCCCCCC VLPFTAMPNXLGLX-UHFFFAOYSA-N 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- 235000019263 trisodium citrate Nutrition 0.000 description 1
- 229960004418 trolamine Drugs 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
Definitions
- the present invention relates to a 0 / W emulsion composition containing difluprednate for eye drops. More specifically, the present invention relates to an ophthalmic 0 / W emulsion composition containing difluprednate, a phospholipid, an oil, and water, which is excellent in the solubility of difluprednate in tears.
- Conventional technology relates to a 0 / W emulsion composition containing difluprednate for eye drops. More specifically, the present invention relates to an ophthalmic 0 / W emulsion composition containing difluprednate, a phospholipid, an oil, and water, which is excellent in the solubility of difluprednate in tears.
- difluprednate used in the present invention is a synthetic corticosteroid exhibiting an excellent anti-inflammatory effect by transdermal administration.
- JP-A-8-217678 discloses that difluprednate is effective for treating ocular inflammation and allergic diseases.
- difluprednate is hardly soluble in water, it cannot be dispensed as with ordinary aqueous eye drops.
- a water-soluble polymer is used as an ophthalmic solution. Discloses a difluprednate suspension having improved dispersibility.
- an aqueous suspension generally has a disadvantage that the feeling of use is poor and that the crystal particles precipitate at the bottom of the container during long-term storage and solidify, and are not evenly dispersed even when shaken vigorously.
- the crystal particles have low solubility in tears, so there is a problem in bioavailability.
- Japanese Patent Application Laid-Open No. 5-186333 and W094 / 05298 disclose 0 / W emulsion composed of drugs, oils, phospholipids and surfactants as a prior art relating to ophthalmic excipients for poorly water-soluble drugs. A composition is disclosed. However, these prior arts do not describe improving the solubility of a poorly water-soluble drug in tears. Disclosure of the invention
- the present invention has been made in view of the problem of a conventional technology for solubilizing a poorly water-soluble drug in water, and an object of the present invention is to provide an ophthalmic composition excellent in the solubility of difluprednate in tears. Is to provide.
- the present inventors have conducted intensive studies to achieve the above-mentioned object, and found that the 0 / W emulsion composition containing difluprednate, phospholipid, oil and water has a solubility of difluprednate in tears. And found that the present invention was significantly improved, and completed the present invention.
- the present invention is a 0 / W emulsion composition containing difluprednate, a phospholipid, an oil, and water (hereinafter sometimes simply referred to as “emulsion”).
- emulsion a 0 / W emulsion composition containing difluprednate, a phospholipid, an oil, and water
- solubility of difluprednate in tears can be adjusted by appropriately changing the mixing ratio of these components.
- the difluprednaton-containing 0 / W emulsion composition of the present invention may be used as an eye drop, as an eye drop, for inflammatory diseases of the external and anterior eye parts, for example, blepharitis, blepharitis, conjunctivitis, keratitis, scleritis, episcleritis It can be effectively applied to the treatment of meningitis, ulceris, iridocyclitis, uveitis, postoperative inflammation, allergic conjunctivitis, catarrh conjunctivitis, spring catarrhal and allergic eye diseases.
- the difluprednate concentration of the ophthalmic difluprednate-containing 0 / W emulsion composition of the present invention is not particularly limited, but is usually 0.002 to 0.5 w / v, preferably 0.002 to 0.6 w / v. / v%.
- concentration of difluprednate is lower than 0.002 w / v%, the concentration of difluprednate dissolved in tears decreases.
- diflup Increasing the concentration of redonate above 0.5 w / v! 3 ⁇ 4 does not improve the dissolution concentration of difluprednate in the tears of the resulting emulsion.
- concentration of difluprednate in the composition is in the range of 0.002 to 0.06 w / v%, the concentration of difluprednate dissolving in tears, particularly a high emulsion can be obtained.
- the "phospholipid” used in the present invention is not particularly limited. Examples include glycerol, dicetyl phosphate, sphingomyelin, synthetic phospholipids such as dimyristoyl phosphatidylcholine, dipalmitoyl phosphatidylcholine or distearoyl phosphatidylcholine, and mixtures of these phospholipids.
- These phospholipids include, for example, Coatsome (registered trademark) NC-10S (high-purity egg yolk lecithin, Nippon Oil & Fats Co., Ltd.), purified egg yolk lecithin (Asahi Kasei Corporation), egg yolk lecithin PL-100H, and PL-100E.
- NC-21 hydrogenated soybean lecithin, Nippon Oil & Fats Co., Ltd.
- egg yolk lecithin LPL-20 egg yolk lecithin LPL-20
- sphingolipid CB-1 sphingolipid, Cupi Co., Ltd.
- coatsome
- MC-6060 L- ⁇ -dipalmitoylphosphatidylcholine, Nippon Oil & Fats Co., Ltd.
- Coatsom II-6060 L-palpaltoyltoylphosphatidic acid, Nippon Oil & Fats Co., Ltd.
- Coatso IMU registered trademark
- MGLS-6060 L- ⁇ -dipalmitoyl phosphatidyl DL-glycerol Na salt, Nippon Oil & Fats Co., Ltd.
- Coatsome registered trademark
- GLA-6060 Li Ichiichi dipalmitoyl phosphatidyl-1 DL —excellent sold under trade names such as glycerol NH 4 salt and NOF Corporation Available at
- the amount of the phospholipid used in the emulsion of the present invention is not particularly limited, but is usually 5 to 80 parts by weight, preferably 5 to 15 parts by weight, per 1 part by weight of difluprednate.
- the amount of the phospholipid used is in the range of 5 to 15 parts by weight per 1 part by weight of difluprednate, an emulsion having a particularly high concentration of difluprednate dissolved in tears can be obtained.
- the amount of the phospholipid used is less than 5 parts by weight per 1 part by weight of difluprednate, crystals of difluprednate are easily precipitated in the emulsion, and it is necessary to prepare an emulsion having a desired difluprednate concentration. It becomes difficult. If the amount of the phospholipid used exceeds 80 parts by weight per 1 part by weight of difluprednate, the dissolution concentration of difluprednate in tears decreases.
- an emulsifying aid may be added to these phospholipids.
- the emulsification aid include sterols such as cholesterol, aliphatic amines such as stearylamine, saturated fatty acids such as stearic acid, palmitic acid, myristic acid, linoleic acid, and oleic acid; And the like, for example, salts that are chemically acceptable (eg, sodium salt ⁇ potassium salt).
- sterols such as cholesterol
- aliphatic amines such as stearylamine
- saturated fatty acids such as stearic acid, palmitic acid, myristic acid, linoleic acid, and oleic acid
- salts that are chemically acceptable eg, sodium salt ⁇ potassium salt
- oil used in the present invention there is no particular limitation on the oil used in the present invention.
- vegetable oils such as soybean oil, sesame oil, corn oil, peanut oil, olive oil, safflower oil, jojoba oil, cottonseed oil, rapeseed oil, etc.
- Mono-, di-, or triglycerides of fatty acids having 6 to 18 carbon atoms such as oil derived from fats and oils, glycerin tricaprylate, tricabrylin, etc. (for example, cabronic acid, stearic acid, panolemitic acid, myristic acid, linoleic acid, etc.)
- mineral oils such as liquid paraffin and light liquid paraffin, silicone oil, fatty acid esters and the like.
- the viscosity and specific gravity of these oils are not particularly limited, and any viscosity and specific gravity can be used in the present invention.
- the composition of the present invention contains at least one selected from these oils. These oils are refined soybean oil (Showa Sangyo Co., Ltd.), refined olive oil (Showa Sangyo Co., Ltd.), NIKK0L safflower oil (Nikko Chemicals Co., Ltd.), NIKK0L jojoba oil E (Nikko Chemicals Co., Ltd.) )), NIKK0L Triesta F-810 (medium chain fatty acid triglyceride, Nikko Chemicals Co., Ltd.), Panassate 810 (medium chain fatty acid tridaliceride, Nippon Yushi Co., Ltd.), NIKKOL TrifatP-52 (hydrogenated palm oil fatty acid) Triglyceride, Nikko Chemicals Co., Ltd.), NIKKOL MGS-A (glycer
- liquid paraffin is suitable for the present invention.
- the amount of the oil used in the emulsion of the present invention is not particularly limited, but is usually 0.5 to 80 parts by weight per 1 part by weight of the phospholipid, and the concentration in the emulsion is 25 w / v or less. It is preferred that When the amount of the oil is 0.5 parts by weight or more based on 1 part by weight of the phospholipid, an emulsion having a particularly high concentration of difluprednate dissolved in tears can be obtained.
- the amount of the oil used is less than 0.5 part by weight per 1 part by weight of the phospholipid, the phospholipid in the emulsion is easily oxidized and the stability of the emulsion is low.
- the amount of oil used exceeds 80 parts by weight per 1 part by weight of the phospholipid, the emulsified system tends to collapse and the emulsion becomes unstable.
- the concentration of the oil in the emulsion exceeds 25 w / v%, the emulsion becomes creamy, and the feeling of use during instillation deteriorates.
- xylitol xylitol, mannitol, Tonicity agents such as polyhydric alcohols such as propylene glycol and glycerin, pH adjusters such as sodium hydroxide and hydrochloric acid, methyl parahydroxybenzoate, parahydroxybenzoate Parabens such as propyl acid, sorbic acid and their pharmaceutically acceptable salts, benzyl alcohol, phenyl alcohol, benzethonium chloride, benzalkonium chloride, chlorhexidine dalconate, oxyquinoline sulfate, chlorobutanol, thimerosal, etc.
- Preservatives synthetic polymers such as methylcellulose, hydroxypropylmethylcellulose, hydroxyethyl cellulose, polyvinylpyrrolidone, polyvinylalcohol, sodium polyacrylate, proteinaceous polymers such as gelatin, dextran, carrageenan Thickeners such as polysaccharides such as chondroitin sodium sulfate, xanthan gum, gum arabic, gum arabic, mouth-casta bean gum, antioxidants such as ascorbic acid, sodium bisulfite, sodium thioglycolate and ⁇ -thioglycerin Agent, acetic acid, phosphoric acid and their pharmaceutically acceptable salts, monoethanolamine, triethano-lamine, boric acid, borax, sodium carbonate, sodium bicarbonate, aminoethylsulfonic acid, £ -aminocaproic acid, sodium chloride
- a buffer such as potassium chloride may be added to water, oil or phospholipid, which is an essential component of the present invention, as long as the
- At least one selected from stabilizing agents such as amino acids, chelating agents, polycarboxylic acid compounds and their pharmaceutically acceptable salts, nonionic water-soluble cellulose derivatives, tocoprole and derivatives thereof, is used.
- stabilizing agents such as amino acids, chelating agents, polycarboxylic acid compounds and their pharmaceutically acceptable salts, nonionic water-soluble cellulose derivatives, tocoprole and derivatives thereof.
- the amino acids used in the present invention include cysteine, histidine and their pharmaceutically acceptable salts (eg, hydrochloride), methionine, phenylalanine, serine and the like.
- Chelating agent used in the present invention polycarboxylic acid compound and their pharmaceutically
- the acceptable salts for example, eel, ethylenediaminetetraacetic acid (hereinafter abbreviated as EDTA), cunic acid, thiomalic acid, L-glutamic acid, succinic acid, malonic acid, maleic acid, dl-malic acid, Adipic acid, tartaric acid, D-tartaric acid, fumaric acid, L-aspartic acid, glycyrrhizic acid, hydroxyethylethylenediamine triacetic acid, diethylenetriaminepentaacetic acid and their pharmaceutically acceptable salts, and L-cystine Is mentioned.
- the composition of the present invention desirably contains at least one selected from these chelating agents, polycarbonate compounds and pharmaceutically acceptable salts thereof.
- Pharmaceutically acceptable salts of EDTA used in the present invention include, for example, sodium edetate, tetrasodium edetate, tetrasodium edetate tetrahydrate, calcium sodium edetate, and the like.
- the pharmaceutically acceptable salts of citrate used in the present invention include, for example, sodium citrate, disodium citrate, trisodium citrate, sodium dihydrogen citrate, calcium citrate, and dihydrogen citrate. Examples thereof include potassium, potassium dihydrogen citrate, and tripotassium citrate monohydrate.
- polycarboxylic acid compounds and their pharmaceutically acceptable salts EDTA, cunic acid and their pharmaceutically acceptable salts, which are widely used as ophthalmic agents, are preferred.
- the amount of the chelating agent, the polycarboxylic acid compound and the pharmaceutically acceptable salt thereof is usually 0.0001 to 0.2 w / v, preferably 0.002 to 0.05 w / v%.
- the non-ionic water-soluble cellulose derivative used in the emulsion of the present invention is not particularly limited.
- composition of the present invention contains at least one selected from these nonionic water-soluble cellulose derivatives.
- methylcellulose and hydroxypropylmethylcellulose are preferred, with methylcellulose being the most preferred.
- the amount of the nonionic water-soluble cellulose derivative to be used is usually 0.0005 to 5 w / v%, preferably 0.02 to 0.5 w / v%.
- Examples of the tocopherol derivative used in the composition of the present invention include tocopheryl acetate, tocoprole nicotinate, and tocoprole succinate.
- the emulsion of the present invention can be sterilized by a filtration sterilization method using a membrane, a heat sterilization method, or the like.
- the emulsion is filled into an ophthalmic bottle, and this is mixed with a polyethylene film together with an oxygen scavenger (eg, Ageless (registered trademark), Mitsubishi Gas Chemical Co., Ltd.). It may be packaged in an aluminum foil laminate bag.
- an oxygen scavenger eg, Ageless (registered trademark), Mitsubishi Gas Chemical Co., Ltd.
- the emulsion of the present invention is usually prepared at pH 4 to 9, but pH 5.5 to 8.0 is preferable from the viewpoint of eye irritation.
- a method for producing the emulsion of the present invention will be described.
- Various known methods are available, for example, egg yolk lecithin and, if desired, a phospholipid such as phosphatidylethanolamine and an emulsifying aid such as oleic acid, and difluprednate in an appropriate form such as hexane, ethanol, etc.
- the solvent is distilled off under reduced pressure to prepare a lipid thin film. Add oil and water, shake vigorously and pre-emulsify. This liquid is emulsified by a commonly used emulsifying machine.
- the pH is adjusted to a target pH with HC1 or NaOH or the like, whereby the 0 / W emulsion containing difluprednate of the present invention can be obtained. Further, after filling this emulsion into an eye drop bottle, it is sterilized to obtain an eye drop of the present invention.
- the present invention will be described in more detail with reference to Examples.
- the instilled drug disappears quickly from the eye surface, which is the main absorption site, due to the turnover of tears. Therefore, the following method was employed for evaluating the solubility of difluprednate in tears of the emulsion of the present invention in order to measure the amount of difluprednate immediately dissolved in tears.
- the artificial tears used in place of the tears were PBSs commonly used for biochemical tests (composition: NaCl 0.8 w / v K, KC 1.02 w / v%, Na 2 HP0 40 . 115w / v 3 ⁇ 4, KH 2 P0 4 0. 02w / v 3 ⁇ 4, PH7. 4) was used. Place this PBS in a 15 mL test tube with a lid. C was kept at a constant temperature in a constant temperature bath. Next, a predetermined amount of emulsion was added to the above PBS, and the mixture was gently inverted at room temperature for 30 seconds. The addition amounts of emulsion and PBS are as follows.
- EPC Egg yolk lecithin
- PYL purified egg yolk lecithin
- difluprednate was dissolved in ethanol, mixed with the above phospholipid solution, and then the solvent was distilled off using an evaporator and then a vacuum pump to form a phospholipid thin film containing difluprednate.
- Liquid paraffin No. 200-S, Sanko Chemical Industry Co., Ltd.
- an aqueous glycerin solution were added to this phospholipid thin film, and vigorously shaken and stirred to perform preliminary emulsification.
- the pre-emulsion was further added with 2! 3 ⁇ 4 glycerin aqueous solution to make up to 100 mL, and passed through 30 times under pressure of 750 kg / cm 2 using a Microfreezer (M-110EH).
- Emulsified 1N NaOH was added to the liquid after the emulsification, and the pH was adjusted to 6.5 to 7.5 to obtain an emulsion of the present invention containing difluprednate.
- To a predetermined amount of difluprednate was added 50 mL of an aqueous solution of glycerin (pH 7.0), dispersed and suspended by stirring and sonication (using BRANS0NIC 12 (manufactured by Branson)). The pH was adjusted to 7.0 with NaOH to prepare a difluprednate suspension.
- Table 1 shows the formulations of the emulsions of the present invention containing difluprednate, and the dissolution concentrations of difluprednate when these difluprednate suspensions were diluted with PBS, or as a comparative example.
- the emulsion of the present invention showed a very high difluprednate dissolution concentration regardless of the dilution ratio of PBS. From these results, the 0 / W emulsion for ophthalmic use of the present invention comprising difluprednate, phospholipid, liquid paraffin and water is excellent in difluprednate solubility in artificial tears.
- Formulation Phospholipid Liquid paraffin difluprednate-diflu dissolved concentration (g / niL) w / v% w / v 3 ⁇ 4 w / v% 21-fold dilution 51-fold dilution
- Emulsion of the present invention is diluted 21, 51-fold with PBS.
- Phospholipid EPC: PYL-7: 3 (weight ratio)
- Dissolution concentration of diflu Dissolution concentration of di 7 leprednate
- the concentration of difluprednate was varied from 0.002 to 0.5 w / v%, and the emulsion of the present invention was obtained in the same manner as in Example 1 below.
- Table 12 shows the formulation of the emulsion of the present invention and the dissolution concentration of difluprednate when these or the difluprednate suspension were diluted 51-fold with PBS as a comparative example.
- Dissolution test The emulsion of the present invention is diluted 51 times with PBS.
- Dissolution concentration of diflu Dissolution concentration of difluprednate
- the emulsion of the present invention was obtained in the same manner as in Example 1 except that the concentrations of difluprednate, phospholipid and liquid paraffin were variously changed. Table 1 shows that And the dissolution concentration of difluprednate when these were diluted 51-fold with PBS.
- difluprednate solubility of difluprednate depends on the concentration of difluprednate in emulsion, the weight ratio of phospholipid to difluprednate, and the weight ratio of oil to phospholipid.
- Dissolution concentration of diflu Dissolution concentration of diflubrednate Formulation Example 1
- Methylcellulose (Metrose (registered trademark) S-100, Shin-Etsu Chemical Co., Ltd.) was dispersed in hot water (70 ° C. or higher) to form a uniform hot water slurry, which was then cooled and dissolved while stirring. Glycerin, chlorobutanol and EDTA disodium are stirred into this. The mixture was dissolved by stirring to prepare a solution of a water-soluble component. To 500 ml of this solution, 500 ml of the emulsion 22 of Formulation 22, prepared in a total volume of 100 mL, was added and mixed well.
- This mixture was adjusted to pH 6.0 with IN HC1, and then filtered through a membrane having a pore size of 0.8 to prepare an emulsion containing the above additives.
- This emulsion was filled into an eye drop bottle and heat sterilized by an intermittent sterilization method to obtain an eye drop of the present invention containing difluprednate. Further, the obtained eye drop of the present invention and Ageless (registered trademark) Z (Mitsubishi Gas Chemical Co., Ltd.) were packaged in a polyethylene film and aluminum foil laminated bag. The procedure is shown below.
- EPC and PYL were dissolved in a mixture of hexanenoethanol (10-1 (v / v)) with stirring.
- difluprednate was dissolved in ethanol, mixed with the above phospholipid solution with stirring, and then the solvent was distilled off using an evaporator followed by a vacuum pump to form a phospholipid thin film containing difluprednate.
- methyl cellulose Metalroz (registered trademark) SM-100, Shin-Etsu Chemical Co., Ltd.
- Glycerin, potassium sorbate and disodium EDTA were dissolved in the solution by stirring to prepare a solution of a water-soluble component.
- This emulsion was filled into an eye drop bottle, and heat sterilized by an intermittent sterilization method to obtain an eye drop of the present invention containing difluprednate. Further, the obtained ophthalmic solution of the present invention and Ageless (registered trademark) Z (Mitsubishi Gas Chemical Co., Ltd.) were packaged in a polyethylene bag and aluminum foil laminated bag. The prescription is shown below.
- the ophthalmic solution of the present invention containing difluprednate was obtained by preparing the emulsion described in Formulation Example 4 by replacing sodium disodium EDTA with sodium citrate and potassium sorbate with benzyl alcohol.
- package the same as Formulation Example 1. went. The prescription is shown below c
- the oil was prepared in place of refined soybean oil (Showa Sangyo Co., Ltd.) to obtain an eye drop of the present invention containing difluprednate. Further, packaging was performed in the same manner as in Preparation Example 1. The prescription is shown below.
- the ophthalmic difluprednate-containing 0 / W emulsion composition of the present invention is excellent in the solubility of difluprednate in tears. Therefore, a sufficient anti-inflammatory effect can be expected at a low dose, and it is economical, and further, it can be expected to reduce systemic side effects that are a concern when instilling difluprednate.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Cette invention concerne une composition de type émulsion huile/eau à usage ophtalmique, laquelle contient du difluprednate, un phospholipide, une huile et de l'eau. Cette composition possède d'excellentes qualités en ce qui concerne la solubilité du difluprednate dans le fluide lacrymal, et possède ainsi un effet anti-inflammatoire satisfaisant même en faible dose. Il est ainsi possible d'améliorer l'efficacité sur le plan économique ou, encore, de réduire les effets adverses systémiques auxquels on peut s'attendre lorsque l'on met des gouttes de difluprednate dans les yeux.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU53424/98A AU5342498A (en) | 1997-01-10 | 1998-01-09 | Difluprednate-containing ophthalmic o/w emulsion composition |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP9/13196 | 1997-01-10 | ||
JP1319697 | 1997-01-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998030221A1 true WO1998030221A1 (fr) | 1998-07-16 |
Family
ID=11826413
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1998/000048 WO1998030221A1 (fr) | 1997-01-10 | 1998-01-09 | Composition de type emulsion huile/eau a usage ophtalmique et contenant du difluprednate |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU5342498A (fr) |
WO (1) | WO1998030221A1 (fr) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0878197A1 (fr) * | 1997-05-14 | 1998-11-18 | Senju Pharmaceutical Co., Ltd. | Compositions à base de difluprednate |
WO2002011734A1 (fr) * | 2000-08-08 | 2002-02-14 | Wakamoto Pharmaceutical Co., Ltd. | Compositions pharmaceutiques aqueuses |
JP3410364B2 (ja) | 1997-05-14 | 2003-05-26 | 千寿製薬株式会社 | ジフルプレドナート含有組成物 |
WO2005082335A1 (fr) * | 2004-02-26 | 2005-09-09 | Kowa Company., Ltd. | Préparation ophtalmique |
JP5138128B2 (ja) * | 1998-08-21 | 2013-02-06 | 千寿製薬株式会社 | 水性液剤 |
WO2014126266A1 (fr) * | 2013-02-15 | 2014-08-21 | Senju Pharmaceutical Co., Ltd. | Composition d'émulsion à base de difluprédnate contenant du zinc |
WO2014126267A1 (fr) | 2013-02-15 | 2014-08-21 | Senju Pharmaceutical Co., Ltd. | Composition d'émulsion de difluprednate contenant un métal antimicrobien |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61249918A (ja) * | 1985-04-26 | 1986-11-07 | Yutaka Mizushima | 点眼剤 |
JPS62270521A (ja) * | 1986-05-16 | 1987-11-24 | Green Cross Corp:The | フルルビプロフエン眼投与製剤 |
JPH05170643A (ja) * | 1991-10-21 | 1993-07-09 | Pola Chem Ind Inc | 水性目薬及びその製造法 |
JPH05186333A (ja) * | 1991-07-05 | 1993-07-27 | Yissum Res Dev Co Of Hebrew Univ Of Jerusalem | 眼用組成物 |
JPH08217678A (ja) * | 1993-12-27 | 1996-08-27 | Senju Pharmaceut Co Ltd | ジフルプレドナート含有点眼用懸濁液剤 |
-
1998
- 1998-01-09 AU AU53424/98A patent/AU5342498A/en not_active Abandoned
- 1998-01-09 WO PCT/JP1998/000048 patent/WO1998030221A1/fr active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61249918A (ja) * | 1985-04-26 | 1986-11-07 | Yutaka Mizushima | 点眼剤 |
JPS62270521A (ja) * | 1986-05-16 | 1987-11-24 | Green Cross Corp:The | フルルビプロフエン眼投与製剤 |
JPH05186333A (ja) * | 1991-07-05 | 1993-07-27 | Yissum Res Dev Co Of Hebrew Univ Of Jerusalem | 眼用組成物 |
JPH05170643A (ja) * | 1991-10-21 | 1993-07-09 | Pola Chem Ind Inc | 水性目薬及びその製造法 |
JPH08217678A (ja) * | 1993-12-27 | 1996-08-27 | Senju Pharmaceut Co Ltd | ジフルプレドナート含有点眼用懸濁液剤 |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3410364B2 (ja) | 1997-05-14 | 2003-05-26 | 千寿製薬株式会社 | ジフルプレドナート含有組成物 |
US6114319A (en) * | 1997-05-14 | 2000-09-05 | Senju Pharmaceutical Co., Ltd. | Compositions containing difluprednate |
EP0878197A1 (fr) * | 1997-05-14 | 1998-11-18 | Senju Pharmaceutical Co., Ltd. | Compositions à base de difluprednate |
JP5138128B2 (ja) * | 1998-08-21 | 2013-02-06 | 千寿製薬株式会社 | 水性液剤 |
US7612115B2 (en) | 2000-08-08 | 2009-11-03 | Wakamoto Pharmaceutical Co., Ltd. | Aqueous pharmaceutical compositions |
WO2002011734A1 (fr) * | 2000-08-08 | 2002-02-14 | Wakamoto Pharmaceutical Co., Ltd. | Compositions pharmaceutiques aqueuses |
WO2005082335A1 (fr) * | 2004-02-26 | 2005-09-09 | Kowa Company., Ltd. | Préparation ophtalmique |
WO2014126266A1 (fr) * | 2013-02-15 | 2014-08-21 | Senju Pharmaceutical Co., Ltd. | Composition d'émulsion à base de difluprédnate contenant du zinc |
WO2014126267A1 (fr) | 2013-02-15 | 2014-08-21 | Senju Pharmaceutical Co., Ltd. | Composition d'émulsion de difluprednate contenant un métal antimicrobien |
US20150374820A1 (en) * | 2013-02-15 | 2015-12-31 | Senju Pharmaceutical Co., Ltd. | Difluprednate emulsion composition containing zinc |
JP2016507468A (ja) * | 2013-02-15 | 2016-03-10 | 千寿製薬株式会社 | 亜鉛を含有するジフルプレドナートエマルション組成物 |
JP2016507469A (ja) * | 2013-02-15 | 2016-03-10 | 千寿製薬株式会社 | 抗菌性金属を含有するジフルプレドナートエマルション組成物 |
RU2666961C2 (ru) * | 2013-02-15 | 2018-09-13 | Сэндзю Фармацевтикал Ко., Лтд. | Эмульсионная композиция дифлюпредната, содержащая антимикробный металл |
Also Published As
Publication number | Publication date |
---|---|
AU5342498A (en) | 1998-08-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8697751B2 (en) | Pharmaceutical composition containing prostaglandin | |
JP5452472B2 (ja) | プロスタグランジン類を含有する眼科用水中油型エマルジョン | |
US6432439B1 (en) | O/W emulsion composition | |
JP2009533462A (ja) | ブリモニジンおよびチモロールの組成物 | |
WO1997005882A1 (fr) | Composition d'emulsion aqueuse pour collyres | |
JP5021887B2 (ja) | アゼチジン誘導体に基づく医薬組成物 | |
JP4933897B2 (ja) | 眼内移行性促進水性点眼剤 | |
JP5593345B2 (ja) | イソプロピルウノプロストンの分解抑制方法 | |
NZ539046A (en) | Chemotherapeutic self-emulsifying microemulsion compositions of paclitaxel with improved oral bioavailability | |
WO1998030221A1 (fr) | Composition de type emulsion huile/eau a usage ophtalmique et contenant du difluprednate | |
RU2348615C2 (ru) | Эмульгирующие системы, содержащие производные азетидина | |
JP6934581B2 (ja) | エピナスチン又はその塩を含有する水性医薬組成物 | |
WO2006004085A1 (fr) | Composition médicinale à base d'eau contenant de l'azithromycine et procédé servant à préparer celle-ci | |
JP2000143542A (ja) | 難溶性免疫抑制剤含有o/wエマルジョン製剤 | |
TW202320774A (zh) | 用於口服之舒緩肽b2受體拮抗劑之基於脂質之組成物 | |
JP2003055201A (ja) | ビタミンa類含有可溶化組成物及びビタミンa類の安定化方法 | |
JP4221073B2 (ja) | 乳剤用保存剤および乳剤 | |
JP2001172183A (ja) | 眼科用医薬組成物 | |
EP2827838A1 (fr) | Composition pharmaceutique ophtalmique contenant un inhibiteur d'anhydrase carbonique et procédé pour sa préparation | |
US20250032412A1 (en) | Self-emulsifying oil-in-water microemulsion or nanoemulsion, and emulsifying composition | |
JP2003286163A (ja) | ジクロフェナクナトリウム経口製剤 | |
GR1009616B (el) | Οφθαλμικο φαρμακευτικο σκευασμα που περιεχει βρινζολαμιδη και τιμολολη και μεθοδος παρασκευης αυτου |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA CN JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase |